


AMENDMENTS TO THE CLAIMS


This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A compound having affinity to and/or selectivity for P-selectin and having structure of formula Ia:



or a stereo-isomer thereof represented by the following formula Ib:



wherein:

X is ~~an optional group, which~~ represents -O-, -OCH₂-, ~~-CH₂-~~, -S-, -SCH₂-, -NH- or -NHCH₂-;

R¹ represents QR⁴, wherein Q represents -O-, -NH-, -NH-(C=O)-, -O-(C=O), -NH-(C=O)-O- or -NH-(C=O)-NH-; and wherein R⁴ represents ~~any substituent comprising at least one carbon atom~~ a linear or branched alkyl or aryl group or a linear or branched aralkyl or alkaryl group;

R² is ~~a moiety bearing at least one negative charge~~ phosphate, phosphonate, carboxylate, or sulphonate group; and

R³ is ~~any group~~ OH or YR⁵, wherein Y is -O-, -CH₂- or -NH- and R⁵ is a linear or branched alkyl or aryl group or a linear or branched aralkyl or alkaryl group.

2. (Currently amended) The compound according to claim 1, wherein X is ~~not present or represents -O-~~ -OCH₂-.

3. (Currently amended) The compound according to claim 1, wherein Q represents -NH-(C=O)-
or -NH-(C=O)-O-.

4. (Currently amended) The compound according to claim 1, wherein R² is ~~or comprises~~ a phosphate group.

5. (Currently amended) The compound according to claim 1, wherein R³ represents OH ~~or YR⁵~~;
~~wherein Y is O, CH₂ or NH and R⁵ comprises at least one carbon atom.~~


6. (Currently amended) The compound according to claim 1, wherein R⁴ ~~comprises an alkyl moiety, an aromatic moiety or a group comprising an electron withdrawing moiety~~ is substituted with a group selected from the group consisting of nitro, -C(O)alkyl, cyano, -SO₃H, -CCl₃, and -CF₃.

7. (Currently amended) The compound according to ~~claim 6~~ claim 1, wherein R⁴ is a phenyl or naphthalene group.


8-13.(Canceled)

14. (Currently amended) A composition comprising in a pharmaceutically acceptable carrier a compound according to claim 1 or a ~~derivative, salt, conjugate, or solvate, or multimer~~ thereof.

15. (Currently amended) A method for determining whether a compound is capable of binding to P-selectin or a functional equivalent or P-selectin, comprising contacting and incubating the compound to be tested and a predetermined amount of a compound having affinity to and/or selectivity for P-selectin, represented by the formula Ia,



or a stereo-isomer thereof represented by the formula Ib,



wherein:

~~X is an optional group, which represents -O-, -OCH₂-, -CH₂-, -S-, -SCH₂-, -NH- or -NHCH₂-;~~

~~R¹ represents QR⁴, wherein Q represents -O-, -NH-, -NH-(C=O)-, -O-(C=O)-, -NH-(C=O)-O- or -NH-(C=O)-NH-; and wherein R⁴ represents any substituent comprising at least one carbon atom a linear or branched alkyl or aryl group or a linear or branched aralkyl or alkaryl group;~~

~~R² is a moiety bearing at least one negative charge phosphate, phosphonate, carboxylate, or sulphonate group; and~~

~~R³ R¹ can be any group is OH or YR⁵, wherein Y is -O-, -CH₂- or -NH- and R⁵ is a linear or branched alkyl or aryl group or a linear or branched aralkyl or alkaryl group,~~

with a predetermined amount of P-selectin or said functional equivalent of P-selectin and

subsequently determining the amount of the same compound.

16. (Previously presented) A method of treating or inhibiting a disease or condition involving activation and/or overexpression of P-selectin in a mammal inflicted with such a disease, the method comprising administering to the mammal an effective P-selectin inhibiting amount of a composition according to claim 14.

17. (New) The compound according to claim 1, wherein X represents -CH₂-.

18. (New) The compound according to claim 1, wherein Q represents -NH-(C=O)-.

19. (New) The compound according to claim 1, wherein X represents -OCH₂- and Q represents -NH-(C=O)- or -NH-(C=O)-O-.